Go Pro
→ 17 Nobel Prize winners… one startling warning (From Porter & Company) (Ad)tc pixel Free FARN Stock Alerts

Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy logo
GBX 35.39 +0.39 (+1.11%)
As of 09/11/2026 11:25 AM Eastern
Compare

FARN vs. PRTC, ARIX, CIR, TILS, and VSN

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? Faron Pharmaceuticals Oy's main competitors and comparable companies include PureTech Health (PRTC), Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

PureTech Health (LON:PRTC) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
PureTech Health-2,355.32% -31.98% -13.39%
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

PureTech Health has a beta of 0.771, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, indicating that its stock price is 12% more volatile than the broader market.

30.7% of PureTech Health shares are owned by institutional investors. Comparatively, 3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than PureTech Health. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health£4.66M62.83-£91.86M-£46.00N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

In the previous week, PureTech Health had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Faron Pharmaceuticals Oy. PureTech Health's average media sentiment score of 0.34 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company Overall Sentiment
PureTech Health Neutral
Faron Pharmaceuticals Oy Neutral

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 325.46%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Faron Pharmaceuticals Oy
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 10 of the 15 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Faron Pharmaceuticals Oy (LON:FARN) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat Arix Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
Arix Bioscience 105.64%6.41%2.18%

Faron Pharmaceuticals Oy has a beta of 1.121, meaning that its share price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Arix Bioscience Neutral

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 10 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Circassia Group (LON:CIR) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Faron Pharmaceuticals Oy Neutral

3.8% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Circassia Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

Summary

Circassia Group beats Faron Pharmaceuticals Oy on 4 of the 7 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tiziana Life Sciences has higher earnings, but lower revenue than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Tiziana Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Faron Pharmaceuticals Oy Neutral

Summary

Faron Pharmaceuticals Oy beats Tiziana Life Sciences on 6 of the 7 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verseon?

Verseon (LON:VSN) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Verseon's return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

In the previous week, Verseon's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
Verseon Neutral
Faron Pharmaceuticals Oy Neutral

3.8% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Faron Pharmaceuticals Oy beats Verseon on 5 of the 6 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FARN vs. The Competition

Export
MetricFaron Pharmaceuticals OyBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£71.80M£3.86B£7.15B£2.87B
Dividend YieldN/A3.63%2.56%6.22%
P/E Ratio-3.0714.11272.98366.83
Price / SalesN/A1,415.79642.1483,599.70
Price / Cash20.00106.6877.0427.89
Price / Book0.0215.1310.336.33
Net Income-£60.23M-£22.82M£3.49B£5.89B
7 Day Performance-4.74%-4.31%-3.33%-0.69%
1 Month Performance-15.74%0.00%-0.40%0.18%
1 Year Performance-81.37%40.67%19.15%20.03%

Faron Pharmaceuticals Oy Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FARN
Faron Pharmaceuticals Oy
N/AGBX 35.39
+1.1%		N/A-80.8%£71.80MN/AN/A34
PRTC
PureTech Health
2.9804 of 5 stars		GBX 121.60
-3.5%		GBX 508
+317.8%		+4.6%£296.00M£4.66MN/A300
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel